Last reviewed · How we verify
NCT04008784
Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period
trial testing Crisaborole 2% Topical Application Ointment [EUCRISA] in Atopic Dermatitis in 16 participants. Completed in 8 September 2020.
14 July 2020
Quick facts
| Lead sponsor | Clinical Research Center of the Carolinas |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 16 |
| Start date | 16 September 2019 |
| Primary completion | 14 July 2020 |
| Estimated completion | 8 September 2020 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Crisaborole 2% Topical Application Ointment [EUCRISA]
- Triamcinolone Acetonide 0.1% Ointment — full drug profile →
Conditions studied
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
Sponsor
Clinical Research Center of the Carolinas
Who can join
Adults 2 to 79, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is a single-center two arm, open label observational prospective study, that will evaluate the safety and efficacy of crisaborole ointment, 2% alone compared to a combination therapy of crisaborole and a topical corticosteroid (Triamcinolone Acetonide Ointment, 0.1%) over a 8 week period for the treatment of mild to moderate atopic dermatitis.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical Implication of Phosphodiesterase-4-Inhibition.
Schick MA, Schlegel N. · · 2022 · cited 56× · PMID 35163131 · DOI 10.3390/ijms23031209 -
Topical anti-inflammatory treatments for eczema: network meta-analysis.
Lax SJ, Van Vogt E, Candy B, Steele L, et al · · 2024 · cited 22× · PMID 39105474 · DOI 10.1002/14651858.cd015064.pub2
Verify or expand the search:
- PubMed search for NCT04008784
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
- NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
Other Clinical Research Center of the Carolinas trials
Trials by the same sponsor.
- NCT03418610 — Azelaic Acid Foam 15% in the Treatment of Papulopustular Rosacea · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04008784 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Clinical Research Center of the Carolinas
- Last refreshed: 28 April 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04008784.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing